Table 2 NE types
From: Annotation and detection of drug effects in text for pharmacovigilance
Entity type | Description | Examples | |
|---|---|---|---|
Pharmacological_substance | Pharmacological substance that may or may not be approved for human use | Genes/gene products used as therapeutic agents | Echistatin |
Generic drug names | Didanosine | ||
IUPAC and IUPAC-like chemical names of drugs | 5-hydroxy- l -tryptophan | ||
Endogenous substances administered as exogenous drugs | Insulin | ||
Toxins | 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine | ||
Excipients | Isopropyl myristate | ||
Generic or chemical names of metabolites | Threohydrobupropion | ||
Drug brand names | DIAMOX | ||
Names of groups of drugs | Fluoroquinolones | ||
Expressions characterising general classes of drugs | Dopamine D1 receptor antagonist | ||
Disorder | Observation about a medical subject’s body or 
mind
 that
 is considered 
to be abnormal 
or caused 
by 
a
 disease, pharmacological substance or DDI | Medical conditions | Pulmonary embolism |
Abnormality in physiological function | Hyperlocomotion | ||
Pathological process | Fibrosis | ||
Neoplastic process | Intestinal adenocarcinomas | ||
Damage caused by disease or drugs | Cerebellar damage | ||
Mental
 or
 behavioural 
issue | Drug abuse | ||
Injury 
or
 poisoning | Clinical toxicities | ||
Viruses/bacteria | Micrococcus luteus | ||
Sign or symptom | Nausea | ||
Abnormality in clinical attributes or measurements | Increased urine sodium | ||
Subject | An organism, cell line, bacterium or group thereof, whose characteristics are under discussion. The organism may be human or otherwise | General references to groups of subjects | Children |
Names of specific species under discussion | Mice | ||
Names of bacteria under discussion | Klebsiella oxytoca | ||
Expressions that specify a number of subjects | 16 patients | ||
Descriptions of subject characterstics | 50-year old male patient | ||